- Home
- ACXP vs CYCN Comparison
ACXP vs CYCN Comparison
Compare ACXP & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- CYCN
- Stock Information
- Founded
- ACXP 2017
- CYCN 2018
- Country
- ACXP United States
- CYCN United States
- Employees
- ACXP N/A
- CYCN N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- CYCN Health Care
- Exchange
- ACXP Nasdaq
- CYCN Nasdaq
- Market Cap
- ACXP 6.8M
- CYCN 7.6M
- IPO Year
- ACXP 2021
- CYCN N/A
- Fundamental
- Price
- ACXP $4.24
- CYCN $2.53
- Analyst Decision
- ACXP Strong Buy
- CYCN
- Analyst Count
- ACXP 3
- CYCN 0
- Target Price
- ACXP $143.67
- CYCN N/A
- AVG Volume (30 Days)
- ACXP 89.0K
- CYCN 1.1M
- Earning Date
- ACXP 11-12-2025
- CYCN 11-13-2025
- Dividend Yield
- ACXP N/A
- CYCN N/A
- EPS Growth
- ACXP N/A
- CYCN N/A
- EPS
- ACXP N/A
- CYCN N/A
- Revenue
- ACXP N/A
- CYCN $2,174,000.00
- Revenue This Year
- ACXP N/A
- CYCN N/A
- Revenue Next Year
- ACXP N/A
- CYCN N/A
- P/E Ratio
- ACXP N/A
- CYCN N/A
- Revenue Growth
- ACXP N/A
- CYCN N/A
- 52 Week Low
- ACXP $3.80
- CYCN $1.27
- 52 Week High
- ACXP $43.20
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- ACXP 51.39
- CYCN 50.11
- Support Level
- ACXP $3.97
- CYCN $2.17
- Resistance Level
- ACXP $4.85
- CYCN $2.59
- Average True Range (ATR)
- ACXP 0.35
- CYCN 0.33
- MACD
- ACXP -0.02
- CYCN -0.01
- Stochastic Oscillator
- ACXP 23.45
- CYCN 23.53
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.